Application of taxus chinensis volatile oil in preparation of medicine for preventing and / or treating psoriasis

Abstract

The application discloses application of yew volatile oil in preparation of a medicine for preventing and / or treating psoriasis, and belongs to the technical field of traditional Chinese medicine preparations. The yew volatile oil cream provided by the application has a remarkable effect in treating psoriasis, can obviously improve clinical skin lesion symptoms of psoriasis, reduce pathological damage of skin tissues, reduce inflammatory reaction in the body, and improve immunity of the body, etc. Compared with a commercially available treatment drug secukinumab (Cosentyx), the cream can improve inflammatory reaction in the body while treating psoriasis skin lesions; compared with calcipotriene betamethasone (Dermabiotic), the cream has no obvious influence on normal body weight while treating psoriasis, and avoids side effects caused by use of hormones. The yew volatile oil cream prepared by the application has uniform and delicate properties, good stability, no skin irritation, high safety, and is suitable for long-term use. In addition, the cream has a clear prescription, is easy to obtain, has a simple preparation method, and is suitable for mass production.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to application of yew volatile oil in preparation of a medicine for preventing and / or treating psoriasis. BACKGROUND

[0002] Psoriasis is a chronic, recurrent, inflammatory and systemic skin disease mediated by immunity, and its clinical manifestations are scaly erythema or plaques. The onset of psoriasis is related to heredity and environmental factors, and factors such as trauma, drinking, environmental humidity and mental stress can induce or aggravate the occurrence of psoriasis. Psoriasis cannot be cured at present, and patients are prone to relapse after treatment, and thus often need lifelong treatment, which causes serious psychological burden to patients.

[0003] Psoriasis is caused by stimulation of the immune system by various pathogenic factors, resulting in dysfunction of various cells such as dendritic cells, T cells and macrophages, and abnormal intracellular signal transduction, inducing immune system disorder and inflammation, leading to characteristics such as excessive proliferation, abnormal differentiation of epidermal keratinocytes and massive inflammatory cell infiltration. The pathogenesis of psoriasis has not been clear so far. IL-23 / Th17 axis plays an important role in the pathogenesis of psoriasis, and cytokines such as TNF-α, IFN-α and interleukin based on IL-23 / Th17 axis are involved in the pathogenesis of psoriasis and induce the occurrence of psoriasis.

[0004] In recent years, new drugs for treating psoriasis have been continuously developed, but due to the complex and unclear disease condition of psoriasis and the long course of the disease, there is a tendency to relapse, and there is still no specific cure for the disease. Most of the drugs currently used in the treatment of psoriasis in the clinic have adverse reactions and are not suitable for long-term use. The main treatment drugs are: vitamin D3 derivatives (calcipotriol), which have skin irritation symptoms and are prone to cause hypercalcemia at high doses; retinoids (tazarotene, acitretin), which have a slow onset and are prone to cause skin irritation; glucocorticoids (beclometasone dipropionate), which can cause systemic adverse reactions when used for a long time and are prone to relapse after drug withdrawal; calcineurin inhibitors (tacrolimus), which can cause burning and itching and have the risk of causing lymphoma; antibiotics (sulfomycin), which are prone to drug resistance when used for a long time; biological agents (ustekinumab), which have a high risk of discontinuation when used for a long time, and have many adverse reactions such as infusion or injection site reactions and respiratory tract infections; immunosuppressants (cyclosporine A and methotrexate), which have many adverse reactions such as hepatotoxicity, nephrotoxicity and bone marrow suppression; Chinese medicine (Xiaoyin granules), which has a slow onset and often needs to be used in combination. At present, alternative therapy, combination therapy and intermittent therapy are usually used in the clinic to control the symptoms of psoriasis, and new drugs for treating psoriasis are urgently needed.

[0005] Taxus chinensis is a natural anticancer plant with high medicinal value. In addition to the anticancer active ingredient paclitaxel, the branches and leaves contain terpenes, volatile oils, flavonoids, polysaccharides and other active ingredients. Previous studies have found that Taxus extract has good anti-inflammatory and immunomodulatory effects, not only can reduce the expression of inflammatory cells and improve inflammatory reactions, but also can regulate the expression of dendritic cells and IL-17 and other cytokines related to the IL-23 / Th17 axis. In addition, Taxus extract is derived from natural plants, has few side effects, is suitable for long-term use, and has good development potential and application prospect. At present, there is no report on the effect of Taxus volatile oil in the treatment of psoriasis. SUMMARY

[0006] The first object of the present application is to provide a Taxus volatile oil for treating psoriasis, and further objects are to provide the use of Taxus volatile oil in the preparation of a medicine for preventing and / or treating psoriasis, and to provide a preparation method of a Taxus volatile oil cream.

[0007] To achieve the above objects, the present application adopts the following technical solutions:

[0008] In the first aspect, the present application provides the use of Taxus volatile oil in the preparation of a medicine for preventing and / or treating psoriasis.

[0009] In some embodiments of the present application, the Taxus volatile oil is obtained by water vapor distillation or supercritical CO2 extraction of Taxus branches and leaves.

[0010] Further, the conditions of the supercritical CO2 extraction method are as follows: anhydrous ethanol is used as a carrier, the mass ratio of material to carrier is 1:3, the extraction pressure is 270 bar, the extraction temperature is 35℃, the separation temperature is 40℃, and the extraction time is 2.5h.

[0011] Specifically, the Taxus volatile oil A is obtained by water vapor distillation as follows: the Taxus branches and leaves are removed, powdered and sieved through a 50 mesh sieve, and the Taxus powder is soaked in water for water vapor distillation. The distilled liquid is extracted with dichloromethane, and the organic solvent is rotary evaporated under reduced pressure to obtain the Taxus volatile oil A.

[0012] The Taxus volatile oil B is obtained by supercritical CO2 extraction as follows: the Taxus powder is weighed and loaded into an extraction kettle, and a supercritical extraction instrument is used for extraction. Anhydrous ethanol is used as a carrier, the ratio of material to carrier is 1:3, the extraction pressure is 270 bar, the extraction temperature is 35℃, the separation temperature is 40℃, and the extraction time is 2.5h to obtain the Taxus volatile oil B.

[0013] Further, the medicine is an external medicine.

[0014] Still further, the external medicine is a cream.

[0015] Specifically, 100 parts of the cream contains 1-20 parts of the Taxus chinensis volatile oil, 5-20 parts of white petrolatum, 5-20 parts of glycerin monostearate, 5-10 parts of sodium dodecyl sulfate, 5-10 parts of chitosan, and the rest is water.

[0016] In a second aspect, the present application further provides a medicine for preventing and / or treating psoriasis, wherein the active ingredient of the medicine contains the Taxus chinensis volatile oil and a pharmaceutically acceptable carrier.

[0017] Preferably, the Taxus chinensis volatile oil has a mass percentage concentration of 1-20% in the medicine. In the embodiments of the present application, the Taxus chinensis volatile oil with a mass percentage concentration of 5% is used as an example.

[0018] In some embodiments of the present application, the pharmaceutically acceptable carrier is a cream base,

[0019] The cream base contains white petrolatum, glycerin monostearate, sodium dodecyl sulfate, chitosan and water.

[0020] Preferably, the Taxus chinensis volatile oil is obtained by water vapor distillation or supercritical CO2 extraction from Taxus chinensis branches and leaves.

[0021] The supercritical CO2 extraction method has the following conditions: anhydrous ethanol is used as a carrier, the mass ratio of the material to the carrier is 1:3, the extraction pressure is 270 bar, the extraction temperature is 35℃, the separation temperature is 40℃, and the extraction time is 2.5h.

[0022] Specifically, the Taxus chinensis volatile oil A is obtained by water vapor distillation: the Taxus chinensis branches and leaves are cleaned, powdered and sieved through a 50-mesh sieve, the Taxus chinensis powder is soaked in water for water vapor distillation, the distilled liquid is extracted with dichloromethane, and the organic solvent is rotary evaporated under reduced pressure to obtain the Taxus chinensis volatile oil A.

[0023] The Taxus chinensis volatile oil B is obtained by supercritical CO2 extraction: the Taxus chinensis powder is weighed and loaded into an extraction kettle, and then extracted by using a supercritical extraction instrument. Anhydrous ethanol is used as a carrier, the mass ratio of the material to the carrier is 1:3, the extraction pressure is 270 bar, the extraction temperature is 35℃, the separation temperature is 40℃, and the extraction time is 2.5h to obtain the Taxus chinensis volatile oil B.

[0024] The present application further provides a preparation method of a medicine for preventing and / or treating psoriasis, i.e. a Taxus chinensis volatile oil cream, which comprises the following steps:

[0025] (1) white petrolatum and glycerin monostearate are weighed and heated to 70-80℃ to melt and mix to obtain an oil phase;

[0026] (2) sodium dodecyl sulfate, chitosan and pure water are weighed and heated to 70-80℃ to melt and mix to obtain an aqueous phase.

[0027] (3) Add the Taxus volatile oil extract into the oil phase and mix well;

[0028] (5) Add the water phase into the oil phase in a thin stream while stirring until condensation, to prepare the Taxus volatile oil cream (O / W);

[0029] In which, per 100 parts of the cream is made of the following raw materials by weight: Taxus volatile oil 1-20 parts, white vaseline 5-20 parts, glycerol monostearate 5-20 parts, sodium dodecyl sulfate 5-10 parts, chitosan 5-10 parts, and the rest is water.

[0030] Compared with the prior art, the present application has the following beneficial effects:

[0031] ① The Taxus volatile oil cream provided by the present application has remarkable effect in treating psoriasis, can obviously improve the clinical skin lesion symptoms of psoriasis, reduce the pathological damage of skin tissue, reduce the inflammatory reaction in the body, and improve the immunity of the body, etc.

[0032] ② Compared with the commercially available treatment drug Secukinumab (Cosentyx), the cream can improve the inflammatory reaction in the body while treating psoriasis skin lesions; compared with Calcipotriene Betamethasone (Dermabiotic), the cream has no obvious effect on normal body weight while treating psoriasis, and avoids the side effects caused by the use of hormones.

[0033] ③ The Taxus volatile oil cream prepared by the present application has uniform and delicate properties, good stability, no skin irritation, high safety, and is suitable for long-term use. Secondly, the cream has clear composition, is easy to obtain, has simple preparation method, and is suitable for mass production. BRIEF DESCRIPTION OF DRAWINGS

[0034] Figure 1 The skin lesion conditions of the rats in each group with different modeling days.

[0035] Figure 2 The psoriasis skin lesion area and severity index (PASI) scores of the rats in each group. ## P<0.01; compared with the model control group, * P<0.05, ** P<0.01.

[0036] Figure 3Skin histopathology observation (HE, ×200) of each group of rats. A: normal control group; B: model control group; C: Kesanting group; D: De'fend Bao group; E: cream base group; F: Taxus volatile oil A cream group; G: Taxus volatile oil B cream group; H: Taxus flavone cream group. (Black arrow: Munro pustule; orange arrow: thinning or disappearance of granular layer; purple arrow: hyperkeratosis; cyan arrow: papillary up; red arrow: inflammatory cell infiltration; yellow arrow: acanthosis; blue arrow: parakeratosis.)

[0037] Figure 4 Skin histopathology observation score (Baker score) of each group of rats. (Note: compared with the normal control group, ΔΔ P<0.01; compared with the model control group, * P<0.05, ** P<0.01.)

[0038] Figure 5 IL-17A and IL-23 levels in serum of each group of rats. (Note: compared with the normal control group, ΔΔ P<0.01; compared with the model control group, * P<0.05, ** P<0.01.)

[0039] Figure 6 TNF-α, IL-1β and IFN-α levels in serum of each group of rats. (Note: compared with the normal control group, ΔΔ P<0.01; compared with the model control group, * P<0.05, ** P<0.01.)

[0040] Figure 7 Body weight and spleen index of each group of rats. (Note: compared with the normal control group, ΔΔ P<0.01; compared with the model control group, * P<0.05, ** P<0.01.) DETAILED DESCRIPTION

[0041] The application will be further described below in conjunction with specific examples. The following examples are only specific embodiments of the application, and the protection scope of the application is not limited to this.

[0042] Materials and methods

[0043] 1. Experimental animals: 80 SPF Wistar rats, female, body weight (180-200) g, purchased from Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd., production license number: SCXK(Zhe)2020-0002, qualified certificate number: 20230510Aazz0600067901, fed by Zhejiang Province Traditional Chinese Medicine Research Institute Experimental Animal Center, use license number: SYXK(Zhe)2019-0010. The feeding environment: the room temperature is (20±2)℃, the humidity is (60±10)%, the light and dark are alternated for 12h, the standard feed, the free water and food. This study was approved by the Zhejiang Province Traditional Chinese Medicine Research Institute Ethics Committee (Approval No.: Zhezhongyan Animal Ethics Review No.

[2021] 020).

[0044] 2. Experimental drugs: 5% imiquimod cream (Sichuan Mingxin Pharmaceutical Co., Ltd., batch number: 39220301); human interleukin-2 for injection (IL-2, Shandong Quan'gang Pharmaceutical Co., Ltd., batch number: 202206009); calcipotriol betamethasone ointment (Dekubal, LEO Laboratories Limited, batch number: C77987); secukinumab injection (Keshanting, Novartis Pharma Stein AG, batch number: SFXR2); ura sugar (National Pharmaceutical Group Chemical Reagent Co., Ltd., batch number: T20070921). Taxus chinensis leaves (Ningbo Taikang Taxus Biological Engineering Co., Ltd.).

[0045] 3. Main reagents and instruments: white vaseline (Tianjin Zhiyuan Chemical Reagent Co., Ltd., batch number: 2020033B); glycerol monostearate (Macklin, batch number: C14887643); sodium dodecyl sulfate (Hangzhou Lanbo, batch number: 20180928); chitosan (Zhejiang Jinshell Pharmaceutical Co., Ltd., batch number: YYSK-1506001); interleukin-17A (IL-17A), interleukin-1β (IL-1β), interleukin-23 (IL-23), tumor necrosis factor (TNF-α) and interferon-α (IFN-α) enzyme-linked immunosorbent assay (ELISA) kit (Shanghai Enzyme-Linked Biotechnology Co., Ltd., item numbers are m1037365, m1003057, m1003152, m1002859, m1003203, and batch numbers are all Jun2023). Multifunctional enzyme marker (Thermo, USA); Nikon eclipse 80i microscope (Nikon, Japan).

[0046] Example 1

[0047] The Taxus chinensis leaves were removed, powdered and passed through a 50 mesh sieve to obtain Taxus chinensis powder.

[0048] A: The volatile oil of Taxus was extracted by steam distillation. The powder of Taxus was put into a distillation flask, and 10 times of water was added to soak for 1 h. The mixture was heated to micro-boiling and kept for 3 h. The oil-water mixture was collected by condensation. After extraction by dichloromethane, the organic layer was separated, and the organic solvent was dried by rotary evaporation under reduced pressure at 35 °C to obtain the volatile oil of Taxus A.

[0049] B: The volatile oil of Taxus was extracted by supercritical CO2 extraction. The powder of Taxus was put into an extraction kettle, and supercritical extraction instrument was used for extraction. Anhydrous ethanol was used as a carrier, and the mass ratio of material to carrier was 1:3. After the carrier was pumped in, it was soaked for 1 h. The extraction pressure was set to 270 bar, the extraction temperature was set to 35 °C, the separation temperature was set to 40 °C, the extraction time was set to 2.5 h, the CO2 flow rate was set to 2 mL / min, and the extraction liquid was collected. After the solvent was dried by rotary evaporation under reduced pressure at 35 °C, the volatile oil of Taxus B was obtained.

[0050] The flavones of Taxus were extracted by microwave-assisted method. The powder of Taxus was put into a four-necked flask, and 60% ethanol solution was used as the solvent. The ultrasonic power was 550 W, the microwave time was 21 min, the extraction temperature was 60 °C, and the solid-liquid ratio was 32 mL / g. The microwave-assisted extraction was carried out by using a microwave extraction workstation. The extraction liquid was concentrated and dried by rotary evaporation to obtain the total flavones of Taxus.

[0051] Example 2

[0052] Preparation of Taxus extract cream (O / W): prescription composition, Taxus extract (drug), white vaseline (oil phase, lubricant), glycerol monostearate (oil phase, auxiliary emulsifier), sodium dodecyl sulfate (emulsifier), chitosan (thickening agent, humectant, preservative), distilled water (aqueous phase).

[0053] Specific preparation method: white vaseline 4.5 g, glycerol monostearate 3.0 g were placed in a centrifuge tube, and heated in a water bath at 80 °C to melt, mixed evenly, to prepare the oil phase; sodium dodecyl sulfate 1.5 g, chitosan 1.5 g and distilled water 16 mL were placed in another centrifuge tube, and heated in a water bath at 80 °C to dissolve, to prepare the aqueous phase.

[0054] ① 1.5 g of the volatile oil extract of Taxus prepared in Example 1 was added to the oil phase and mixed evenly. Finally, the aqueous phase was added to the oil phase in a thin stream, stirred while adding, and then made up to 30 g with water until condensation, to prepare a 5% volatile oil cream of Taxus (O / W).

[0055] ② 3.0 g of the flavone extract of Taxus prepared in Example 1 was added to the aqueous phase and mixed evenly. Finally, the aqueous phase was added to the oil phase in a thin stream, stirred while adding, and then made up to 30 g with water until condensation, to prepare a 10% flavone cream of Taxus (O / W).

[0056] Example 3

[0057] Grouping and modeling: 80 SPF female Wistar rats were randomly divided into normal control group, model control group, secukinumab group (Cosentyx), calcipotriol betamethasone group (Diflor), cream base group, taxus volatile oil A cream group, taxus volatile oil B cream group, taxus flavone cream group, a total of 8 groups, 10 rats in each group.

[0058] After the rats were adaptively fed for several days, the hair on the central area (2 cm x 2 cm) of the back of each rat was shaved off, and the surface short hair was removed with a mild depilatory cream, washed and dried for use. If the back hair grows during the experiment, the hair is removed again with a depilatory cream. In the morning every day, except for the normal control group, the rest of the rats in each group were injected with IL-2 injection (90,000 IU / kg) intraperitoneally, and 20 mg / cm 2 Uniformly apply 5% imiquimod cream; the normal control group of rats was applied with an equal amount of vaseline on the back, 1 time / d, for 10 consecutive days.

[0059] Dosing: In the afternoon every day, the normal control group and the model control group were not treated, the calcipotriol betamethasone group of rats was applied with calcipotriol betamethasone cream on the back, the cream base group of rats was applied with cream base on the back, the taxus extract group of rats was applied with the corresponding drug-containing cream on the back, the amount was 0.2 g per rat, 1 time / d, for 10 consecutive days. The secukinumab group of rats was only subcutaneously injected with secukinumab injection 30 mg / kg on the 3rd day of the experiment.

[0060] 1. The effect of different taxus extract creams on the psoriasis area and severity index (PASI) score of rats

[0061] According to the PASI score standard, the rats were given scores of 0-4 for the degree of erythema, scales and epidermal infiltration thickening on the lesion. The scoring criteria are as follows: 0, none; 1, mild; 2, moderate; 3, severe; 4, extremely severe, see Table 1 for details. The scores of each group of rats were averaged, and the changes in the lesions of each group of rats were observed daily.

[0062] For example Figure 1As shown, the model control group rats showed light red skin on the 2nd day of modeling; on the 4th day, the skin was obviously thickened, and different degrees of erythema and scales appeared; on the 6th day, the skin was deep red, almost covered with thick and layered scales, and the skin thickening was more obvious; on the 8th to 10th day, most of the skin was covered with scales, and the erythema and skin thickening were obvious. On the 10th day, the skin of the normal control group was smooth, flat, and undamaged; most of the skin of the model control group was covered with scales, was deep red, and was obviously thickened; the skin of the Keshisan group was partially covered with scales, was deep red, and was obviously thickened; the skin of the De-fu-bao group had a small amount of scales or no scales, was deep red, and was obviously thickened; the skin of the cream base group was mostly covered with scales, was deep red, and was obviously thickened; the skin of the Taxus volatile oil A cream group had a small amount or part of scales, was light red, and was slightly thickened; the skin of the volatile oil B cream group had a small amount or no scales, was light red, and was slightly thickened; the skin of the flavone cream group had part of scales, was deep red, and was obviously thickened.

[0063] As shown in Table 2, the PASI score of the normal control group rats basically maintained at 0-2 points; the PASI score of the model control group rats gradually increased, reached a peak on the 5th day, and then tended to be stable; the PASI scores of the various administration groups were reduced to different degrees compared with the model control group. Figure 2

[0064] 2. Effects of different Taxus extracts on the histopathology of the skin tissue of psoriasis rats

[0065] Histopathological observation of the skin tissue: After blood sampling, the rats were sacrificed. The skin lesion tissue on the back of the rats was taken, fixed with 4% neutral formaldehyde, dehydrated, embedded in paraffin, sectioned, and then stained with HE, and the morphological changes of the skin tissue were observed under a microscope to conduct Baker scoring.

[0066] The specific standards of Baker scoring are as follows: 2.0 points for finding Munro abscess in the epidermis layer; 0.5 points for hyperkeratosis; 1.0 points for parakeratosis; 1.0 points for thinning or disappearance of the granular layer; 1.0 points for thickening of the prickle layer; 0.5 points, 1.0 points, and 1.5 points for elongation and undulation of the skin process according to mild, moderate, and severe degrees; 0.5 points, 1.0 points, and 1.5 points for mononuclear or multinuclear cell infiltration in the dermis layer according to mild, moderate, and severe degrees; 0.5 points for papillary up; and 0.5 points for capillary dilation.

[0067] As shown in Table 2, the PASI score of the normal control group rats basically maintained at 0-2 points; the PASI score of the model control group rats gradually increased, reached a peak on the 5th day, and then tended to be stable; the PASI scores of the various administration groups were reduced to different degrees compared with the model control group. Figure 3 ​As shown in the figure, the normal control group skin structure is complete and clear, the granular layer is clearly visible, the epidermis is slightly keratinized, no acanthosis, parakeratosis, capillary dilation, only a small amount of inflammatory cell infiltration in the dermis; model control group and cream base group skin can be seen hyperkeratosis, parakeratosis, acanthosis, thinning or disappearance of the granular layer, skin protrusions, inflammatory cell infiltration and capillary dilation, and other psoriasis pathological features; the pathological features of each administration group were reduced to varying degrees.

[0068] As shown in the figure, compared with the normal control group, the Baker score of the model control group was significantly increased (P<0.01); compared with the model control group, the Baker scores of the Kushanting, Taxus volatile oil A and B cream groups were significantly reduced (P<0.05, 0.01). Figure 4

[0069] 3. Effects of different extracts of Taxus on serum inflammatory factors in psoriasis rats

[0070] ELISA detection of IL-17A, TNF-α, IL-23, IFN-α and IL-1β levels in serum: after the modeling was completed, the rats were anesthetized with 20% urethane (1400 mg / kg), and blood was collected from the abdominal aorta, centrifuged at 3500 r / min for 15 min, and the serum was separated. The levels of IL-17A, TNF-α, IL-23, IFN-α and IL-1β in serum were detected by enzyme-linked immunosorbent assay (ELISA) according to the kit instructions.

[0071] As shown in the figure, compared with the normal control group, the Baker score of the model control group was significantly increased (P<0.01); compared with the model control group, the Baker scores of the Kushanting, Taxus volatile oil A and B cream groups were significantly reduced (P<0.05, 0.01). Figure 5 Figure 6 As shown in the figure, compared with the normal control group, the Baker score of the model control group was significantly increased (P<0.01); compared with the model control group, the Baker scores of the Kushanting, Taxus volatile oil A and B cream groups were significantly reduced (P<0.05, 0.01).

[0072] 4. Effects of different extracts of Taxus on spleen index in psoriasis rats

[0073] Spleen index: dissection, take the spleen tissue, weigh and calculate the spleen index.

[0074] ​​Psoriasis is a chronic inflammatory disease, long-term inflammatory stimulation can lead to abnormal immune function, and induce the enlargement of immune organs such as spleen. Figure 7 As shown in Fig. 2, compared with the normal control group, the body weight of the De'fubao group was significantly reduced (P<0.01), which was due to the side effects of long-term use of hormone drugs; the spleen index of the model control group was significantly increased (P<0.01). Compared with the model control group, the spleen index of the De'fubao group and the volatile oil B cream group was significantly reduced (P<0.01, 0.05).

[0075] The statistical methods above were used to statistically analyze the data by SPSS 20.0. The data were expressed as The one-way ANOVA was used for comparison among multiple groups, and the LSD-t test was used for comparison between two groups. For data not conforming to normal distribution or variance, the Mann-Whitney U test was used. P<0.05 was considered statistically significant.

[0076] In summary, the Taxus volatile oil cream has obvious therapeutic effect on psoriasis, which can improve the clinical symptoms of psoriasis such as erythema, scales and thickening of the epidermis, reduce the PASI score of skin lesions and the Baker score of skin histopathology, improve the inflammatory response in vivo, and improve the immunity of the body, and has good development potential and application prospect.

Claims

1. Application of Taxus chinensis volatile oil in the preparation of drugs for the prevention and / or treatment of psoriasis.

2. Use according to claim 1, wherein The volatile oil of yew is obtained by steam distillation or supercritical CO2 extraction from yew branches and leaves.

3. Use according to claim 2, wherein the compound is ###0002### The conditions for the supercritical CO2 extraction method are as follows: anhydrous ethanol is used as the entrainer, the mass ratio of material to entrainer is 1:2 to 1:3, the extraction pressure is 240 to 280 bar, the extraction temperature is 33 to 37°C, the separation temperature is 40 to 45°C, and the extraction time is 1 to 3 hours.

4. The use according to claim 1, wherein The drug is for external use only.

5. The use according to claim 4, wherein the compound is ###0002### The topical medication is a cream.

6. Use according to claim 5, wherein Every 100 parts of the cream contains 1-20 parts of yew volatile oil, 5-20 parts of white petrolatum, 5-20 parts of glyceryl monostearate, 5-10 parts of sodium lauryl sulfate, 5-10 parts of chitosan, and the remainder is water.

Images